-
1.发明申请公开(公告)号：US20170240636A1
公开(公告)日：2017-08-24
申请号：US15515461
申请日：2015-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzamme J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/31
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
2.发明申请公开(公告)号：US20200247890A1
公开(公告)日：2020-08-06
申请号：US16842885
申请日：2020-04-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xavier Valencia , John P. Throup , Steven G. Nadler , Suzanne J. Suchard , Dominique Duchesne , Xiaoni Liu , Rong Shi , Diane E. Shevell , Jenny H. Xie , Marek Honczarenko
IPC: C07K16/28 , A61K47/60 , A61K39/395 , A61K45/06
Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.
-
公开(公告)号：US20180142023A1
公开(公告)日：2018-05-24
申请号：US15870121
申请日：2018-01-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K45/06 , A61K39/395 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
公开(公告)号：US09908937B2
公开(公告)日：2018-03-06
申请号：US14740709
申请日：2015-06-16
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
公开(公告)号：US10919965B2
公开(公告)日：2021-02-16
申请号：US15870121
申请日：2018-01-12
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
Patent Agency Ranking
公开(公告)号：US20190086405A1
公开(公告)日：2019-03-21
申请号：US16085007
申请日：2017-03-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Laurence Celine Menard , Steven G. Nadler
IPC: G01N33/564
Abstract: In certain embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) identifying the subject as having at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (b) administering an agent that inhibits the CD40 or CD28 signaling pathway, thereby treating or preventing lupus in the subject. In other embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) administering an agent that inhibits the CD40 or CD28 signaling pathway; (b) determining whether the agent neutralizes at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (c) adjusting the dosing of the agent in the subject, thereby treating or preventing lupus in the subject.
-
公开(公告)号：US20150299321A1
公开(公告)日：2015-10-22
申请号：US14740709
申请日：2015-06-16
Applicant: Bristol-Myers Squibb Company , Domantis Ltd.
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
Abstract translation: 公开了单价结合CD28的结构域抗体。 对CD28结合而言是单价的域抗体可抑制CD28活性。 在一个方面，结构域抗体由一个方面组成或包含单个免疫球蛋白可变区，其特异性结合并拮抗CD28的活性，一方面，没有实质上激动的CD28活性。 另一方面，结构域抗体是人结构域抗体。 本公开还包括在个体中拮抗CD80和/或CD86相互作用的方法以及涉及与CD28相互作用的CD80和/或CD86相互作用的疾病或病症的方法，所述方法涉及对个体施用结构域抗体。
-
公开(公告)号：US08981072B2
公开(公告)日：2015-03-17
申请号：US14101441
申请日：2013-12-10
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Steven G. Nadler , James K. Tamura , Laura Price , Robert P. Rehfuss , Suzanne J. Suchard , Anish Suri , James William Bryson , Aaron Yamniuk , Steven Grant , Olga Ignatovich , Philip Drew
IPC: C12N15/13 , C12N15/12 , C12N5/10 , C07K16/28 , A61K39/395 , A61K45/06 , C07K16/46 , A61K39/00 , A61K38/00
CPC classification number: C07K16/2878 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/283 , C07K16/2833 , C07K16/2875 , C07K16/2896 , C07K16/46 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30
Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
Abstract translation: 提供了特异性结合人CD40L的抗体多肽。 抗体多肽不激活血小板。 抗体多肽可用于治疗涉及CD40L活化的疾病，例如移植物相关疾病和自身免疫性疾病。 抗体多肽可以是包含单个VH或VK结构域的结构域抗体（dAb）。 抗体多肽的半衰期可以通过将抗体多肽修饰为也可以结合人血清白蛋白（HSA）或另一抗原的双特异性试剂来增加。
-
公开(公告)号：US12012452B2
公开(公告)日：2024-06-18
申请号：US17086565
申请日：2020-11-02
Applicant: Bristol-Myers Squibb Company , Domantis Limited
Inventor： Murray McKinnon , Steven G. Nadler , Suzanne J. Suchard , Brendan Classon , Steve Holmes , Olga Ignatovich , Christopher Plummer , Steve Grant
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61P37/06 , A61K39/00
CPC classification number: C07K16/2818 , A61K39/3955 , A61K45/06 , C07K16/2896 , A61K2039/505 , C07K2317/31 , C07K2317/569 , C07K2317/73
Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
-
公开(公告)号：US20230236188A1
公开(公告)日：2023-07-27
申请号：US18152056
申请日：2023-01-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Laurence Celine Menard , Steven G. Nadler
IPC: G01N33/564
CPC classification number: G01N33/564 , G01N2333/70532 , G01N2333/70578 , G01N2800/104 , G01N2333/70596 , G01N2333/70521 , G01N2333/70575 , G01N2800/52 , G01N2800/60
Abstract: In certain embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) identifying the subject as having at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (b) administering an agent that inhibits the CD40 or CD28 signaling pathway, thereby treating or preventing lupus in the subject. In other embodiments, the present invention provides a method of treating or preventing lupus (e.g., SLE) in a subject, comprising: (a) administering an agent that inhibits the CD40 or CD28 signaling pathway; (b) determining whether the agent neutralizes at least one differentially regulated biomarker selected from CD40, CD40L, CD86, CD80, and PD1; and (c) adjusting the dosing of the agent in the subject, thereby treating or preventing lupus in the subject.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.028 seconds)
